Clinical, electrophysiological, cutaneous sensory, and autonomic changes in patients with multiple myeloma following bortezomib treatment
Young Gi Min, Seungjin Choi, Yoo Jin Lee, Youjin Kim, Jae‐Cheol Jo, Sunyoung Kim
Yonsei University Severance Hospital Ulsan University Hospital University of Ulsan
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Background: Bortezomib-induced peripheral neuropathy (BIPN) is a significant adverse effect following bortezomib administration for multiple myeloma (MM). The clinical presentation of BIPN, its predictive factors, and the role of pre-existing neuropathy remain unclear. This study aimed to provide comprehensive clinical and electrophysiological profiles of BIPN, its baseline predictors, and the role of pre-existing neuropathy.Methods: This prospective longitudinal observational study involved 27 patients with newly diagnosed MM. Their neurological features were assessed before and after four cycles of bortezomib-based chemotherapy using four validated outcome measures and three types of electrophysiological testing: the reduced Total Neuropathy Score (TNS-r), Composite Autonomic Symptom Score-31, Small Fiber Neuropathy Symptom Inventory Questionnaire, Korean Neuropathic Pain Questionnaire, nerve conduction studies, quantitative sensory testing, and quantitative sudomotor axon reflex testing (QSART).Results: Bortezomib treatment significantly worsened the TNS-r (p = 0.0033), primarily due to sensory symptoms and signs, with cold pain being the most-affected sensory symptom. Significant deterioration was also observed in the sensory nerve action potential (SNAP) amplitude, cold detection threshold, and QSART score. Baseline predictors of clinically evident BIPN (TNS-r ≥3) were the ulnar compound muscle action potential amplitude, median SNAP amplitude, and QSART score. Some patients with baseline neuropathic pain or autonomic dysfunction experienced considerable improvement following treatment.Conclusions: BIPN primarily causes sensory symptoms and axonal degeneration, and may be predicted by several baseline electrophysiological parameters. The unexpected improvement in pre-existing neuropathic pain and autonomic symptoms during chemotherapy in some patients warrants further clinical and mechanistic investigations.
逐年被引趋势
暂无年度引用数据
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Cancer Treatment and Pharmacology
Multiple Myeloma Research and Treatments · Peripheral Neuropathies and Disorders